Okyo Pharma (OKYO) Limited announced that it intends to offer to sell its ordinary shares in an underwritten public offering. All of the ordinary shares are to be sold by the company. The company intends to use the net proceeds from the offering primarily for clinical development of its product candidates, general corporate purposes and working capital. Piper Sandler & Co. is acting as the sole book-running manager for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKYO:
- OKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push
- OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners
- OKYO Pharma Hires Oxervate Veteran Flavio Mantelli as Chief Medical Officer to Drive Urcosimod Program
- Okyo Pharma appoints Mantelli as Chief Medical Officer
- OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial